178 related articles for article (PubMed ID: 8750529)
1. INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.
Pauley RJ; Gimotty PA; Paine TJ; Dawson PJ; Wolman SR
Breast Cancer Res Treat; 1996; 37(1):65-76. PubMed ID: 8750529
[TBL] [Abstract][Full Text] [Related]
2. Genetic markers as prognostic indicators in breast cancer.
Wolman SR; Pauley RJ; Mohamed AN; Dawson PJ; Visscher DW; Sarkar FH
Cancer; 1992 Sep; 70(6 Suppl):1765-74. PubMed ID: 1355402
[TBL] [Abstract][Full Text] [Related]
3. Amplification of fgfr4 gene in human breast and gynecological cancers.
Jaakkola S; Salmikangas P; Nylund S; Partanen J; Armstrong E; Pyrhönen S; Lehtovirta P; Nevanlinna H
Int J Cancer; 1993 May; 54(3):378-82. PubMed ID: 8099571
[TBL] [Abstract][Full Text] [Related]
4. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.
Konopka B; Janiec-Jankowska A; Paszko Z; Goluda M
J Cancer Res Clin Oncol; 2004 Feb; 130(2):114-21. PubMed ID: 14663583
[TBL] [Abstract][Full Text] [Related]
5. The association of HER-2/neu amplification with breast cancer recurrence.
Carr JA; Havstad S; Zarbo RJ; Divine G; Mackowiak P; Velanovich V
Arch Surg; 2000 Dec; 135(12):1469-74. PubMed ID: 11115354
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
[TBL] [Abstract][Full Text] [Related]
7. GST pi gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers.
Saint-Ruf C; Malfoy B; Scholl S; Zafrani B; Dutrillaux B
Oncogene; 1991 Mar; 6(3):403-6. PubMed ID: 1826346
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-risk breast cancer patients from genetic changes of their tumors.
Watatani M; Inui H; Nagayama K; Imanishi Y; Nishimura K; Hashimoto Y; Yamauchi E; Hojo T; Kotsuma Y; Yamato M; Matsunami N; Yasutomi M
Surg Today; 2000; 30(6):516-22. PubMed ID: 10883462
[TBL] [Abstract][Full Text] [Related]
9. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
10. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.
Borg A; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Olsson H; Killander D; McGurie WL
Br J Cancer; 1991 Jan; 63(1):136-42. PubMed ID: 1989653
[TBL] [Abstract][Full Text] [Related]
11. ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
[TBL] [Abstract][Full Text] [Related]
12. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
[TBL] [Abstract][Full Text] [Related]
13. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
[TBL] [Abstract][Full Text] [Related]
14. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
15. int-2 oncogene amplification and prognosis in node-negative breast carcinoma.
Fioravanti L; Cappelletti V; Coradini D; Miodini P; Borsani G; Daidone MG; Di Fronzo G
Int J Cancer; 1997 Dec; 74(6):620-4. PubMed ID: 9421359
[TBL] [Abstract][Full Text] [Related]
16. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.
Roux-Dosseto M; Romain S; Dussault N; Desideri C; Piana L; Bonnier P; Tubiana N; Martin PM
Eur J Cancer; 1992; 28A(10):1600-4. PubMed ID: 1356387
[TBL] [Abstract][Full Text] [Related]
17. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
Ottestad L; Andersen TI; Nesland JM; Skrede M; Tveit KM; Nustad K; Børresen AL
Acta Oncol; 1993; 32(3):289-94. PubMed ID: 8100712
[TBL] [Abstract][Full Text] [Related]
18. FGF4 and INT2 oncogenes are amplified and expressed in Kaposi's sarcoma.
Kiuru-Kuhlefelt S; Sarlomo-Rikala M; Larramendy ML; Söderlund M; Hedman K; Miettinen M; Knuutila S
Mod Pathol; 2000 Apr; 13(4):433-7. PubMed ID: 10786811
[TBL] [Abstract][Full Text] [Related]
19. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
20. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
